Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

BACKGROUND: Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements. Guidelines, however, recommend measuring emicizumab concentrations when the presence of antidrug antibodies is s...

Descripción completa

Detalles Bibliográficos
Autores principales: Donners, Anouk A. M. T., Gerencsér, László, van der Elst, Kim C. M., Egberts, Toine C. G., de Maat, Moniek P. M., Huisman, Albert, Urbanus, Rolf T., El Amrani, Mohsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Methodological Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175248/
https://www.ncbi.nlm.nih.gov/pubmed/35702589
http://dx.doi.org/10.1002/rth2.12725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175248/
https://www.ncbi.nlm.nih.gov/pubmed/35702589
http://dx.doi.org/10.1002/rth2.12725

Ejemplares similares